Novavax (NVAX) Competitors

Novavax (NASDAQ:NVAX) and Amicus Therapeutics (NASDAQ:FOLD) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, community ranking, earnings and risk.

Is NVAX or FOLD more profitable?

Amicus Therapeutics has a net margin of -10.62% compared to Novavax's net margin of -32.18%. Amicus Therapeutics' return on equity of 12.44% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-32.18%	N/A	-17.05%
Amicus Therapeutics	-10.62%	12.44%	2.60%

Which has more volatility & risk, NVAX or FOLD?

Novavax has a beta of 2.92, meaning that its stock price is 192% more volatile than the S&P 500. Comparatively, Amicus Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500.

Do analysts rate NVAX or FOLD?

Novavax presently has a consensus target price of $18.00, suggesting a potential upside of 136.84%. Amicus Therapeutics has a consensus target price of $16.75, suggesting a potential upside of 85.90%. Given Novavax's higher probable upside, research analysts clearly believe Novavax is more favorable than Amicus Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Amicus Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Which has higher valuation and earnings, NVAX or FOLD?

Amicus Therapeutics has lower revenue, but higher earnings than Novavax. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Novavax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$682.16M	1.79	-$545.06M	-$1.33	-5.71
Amicus Therapeutics	$528.30M	5.24	-$151.58M	-$0.18	-50.06

Does the media prefer NVAX or FOLD?

In the previous week, Amicus Therapeutics had 6 more articles in the media than Novavax. MarketBeat recorded 8 mentions for Amicus Therapeutics and 2 mentions for Novavax. Amicus Therapeutics' average media sentiment score of 1.47 beat Novavax's score of 0.85 indicating that Amicus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amicus Therapeutics	8 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals and insiders hold more shares of NVAX or FOLD?

53.0% of Novavax shares are held by institutional investors. 1.0% of Novavax shares are held by insiders. Comparatively, 2.2% of Amicus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the MarketBeat Community prefer NVAX or FOLD?

Novavax received 319 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. Likewise, 74.06% of users gave Novavax an outperform vote while only 72.98% of users gave Amicus Therapeutics an outperform vote.

Company	Underperform	Outperform
Novavax	Outperform Votes 851 74.06%	Underperform Votes 298 25.94%
Amicus Therapeutics	Outperform Votes 532 72.98%	Underperform Votes 197 27.02%

Summary

Amicus Therapeutics beats Novavax on 11 of the 18 factors compared between the two stocks.